A pivotal Phase 2b study of Betalutin in patients with relapsed 3rd line anti-CD 20 Ab-refractory Follicular Lymphoma
Phase of Trial: Phase II
Latest Information Update: 04 Apr 2018
At a glance
- Drugs Lutetium-(177lu) lilotomab satetraxetan (Primary)
- Indications Follicular lymphoma
- Focus Registrational; Therapeutic Use
- Acronyms PARADIGME
- Sponsors Nordic Nanovector
- 04 Apr 2018 According to a Nordic Nanovector media release, due to re-assessment in recruitment rate, company has to revised its timeline for this study. Company expects to dose first patient in 1H 2018 and expects results in 1H 2020 and first regulatory filing in 2020.
- 27 Feb 2018 According to a Nordic Nanovector ASA media release, this trial was initiated in the fourth quarter of 2017.
- 27 Feb 2018 According to a Nordic Nanovector ASA media release, status changed from planning to recruiting.